Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Aug 13, 2022 12:31pm
441 Views
Post# 34894008

RE:RE:RE:SP

RE:RE:RE:SP

AP

We'll soon have the answer to your "fair price" question.

Shades of July '21 ?

In any event, IMO, any raise below, $ 2 - $ 3 is dilutive, and likely greed - motivated. 

The only question is whether in H2 2022, they'll select brand new identities for BayStreetWild, GoldMember, etc., assisted by stalwarts like Stocktree, and leave loyal investors ( the ones that brung them) to watch in disgust as shares go for a song, post financing.  Although maybe this year, there will be less of an incentive to take advantage of tax loss selling season ( complete with some short selling and buy-backs) 

And will JK be able to show his face at meetings with less than 8-10 enrollees per month when flu season hits next month ( Note Australia and NZ have reported a heavy rebound in flu for their winters) ? Moving to 25 sites now ? Pray monkey- pox doesn't overrun the ICUs 

Strategic accumulation of a higher % at artificially low prices  is the name of the game.  Always has been.   The science and the hope and promise of saving lives appears to be secondary.  Until that is, someone gives the signal that they have enough. 

Thinly traded Spectral, operating off-off-off broadway by design marches to its own drummer dictated by Mgt under the " watchful" eye of the BoD. The first down leg of the market in spring 2022 was defied by the # 12 horse. The next move, likely this fall or winter, will prove equally irrelevant to the less than 50 real traders, rowing more or less in unison To the calls of the coxswain. 

Sad that the rest of us have to endure the squeezing out of so many shares in order to get the average Cost of a few down by 7 cents - when many $ / share ultimate proceeds IS the writing on the wall, of the gas-lit room. 40 million more is my guess. Which has the odor of rewarding incompetence, couched with some legitimate excuses. 


MM
 
 

<< Previous
Bullboard Posts
Next >>